statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

While most of the corporates have shown double digit value growth, unit growth remains a challenge for the Indian pharma market, according to analysts

Indian pharmaceutical market registers 9.5% growth in March

Mankind's new subsidiary will have an initial paid-up capital of Rs 5 crore with a further investment of up to  Rs 250 crore in one or more tranches, the press statement added.

Mankind Pharma to sell OTC business on a slump sale basis in yet-to-be subsidiary

The offer price for the transaction is likely to be around Rs 2,103-2,214 apiece, a discount of up to 5 percent Mankind Pharma's previous close.

Mankind Pharma sees Rs 2,736.8 cr block deal as ChrysCapital affiliate offloads stake

Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.

Strong India growth, benign price erosion in the US drive Q3 earnings for Indian pharma

Various drugs manufactured by listed players like Sun Pharmaceuticals, Alkem Laboratories, Cipla Ltd, Mankind Pharma, Lupin Ltda and Torrent Pharma are included in the list.

Diabetes, BP drugs to cost less as NPPA fixes retail prices of 69 formulations

Around 70% of stocks in Nifty MidCap 100 and Nifty SmallCap 100 indices witnessed a rise in mutual fund stakes in December 2023 quarter, according to Ace Equities data.

MFs raise stakes in 70% Nifty smallcap, midcap stocks in Q3, despite caution

Cancer medication Trastuzumab manufactured by Hetero Biopharma Limited and Mankind Pharma Limited will have a ceiling price of Rs 15817.49 per vial.

Drug pricing watchdog fixes retail rates for 19 formulations, including cancer pills

Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. It offers products under the brands of Nurokind, Telmikind, Manforce, Unwanted, Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Prega News, Dydroboon, Cefakind, Monticope, and Caldikind. The company was founded by Ramesh Chand Juneja in 1986 and is headquartered in New Delhi, India.

Volume	197,510.00
52-Wk High	2,490.00
52-Wk Low	1,242.00

Current Price	2,373.80
Prev Close	2,397.00
Open	2,398.55
Dividend Yield	N/A
50-Day Moving Average	2,224.75
Beta	-0.23
Avg. Volume	1.09M
PE Ratio	55.63

52-Week High	2,490.00
52-Week Low	1,242.00
Market Capitalization	960.73B
EPS	43.11
Price to Book	11.40
Revenue Per Employee	5.39M
Enterprise Value/EBITDA	29.65

MANKIND.NSE Mankind Pharma Ltd.

About

Feed

News

Fundamentals